Geoff Meacham
Stock Analyst at B of A Securities
(3.54)
# 804
Out of 4,641 analysts
209
Total ratings
51.94%
Success rate
4.28%
Average return
Main Sectors:
Stocks Rated by Geoff Meacham
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Neutral | $185 → $195 | $187.88 | +3.79% | 12 | Oct 18, 2024 | |
| TYRA Tyra Biosciences | Upgrades: Buy | $22 → $31 | $28.24 | +9.77% | 2 | Oct 18, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $130 → $115 | $69.98 | +64.33% | 2 | Sep 17, 2024 | |
| MRNA Moderna | Maintains: Neutral | $130 → $110 | $53.39 | +106.03% | 9 | Sep 13, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $42 | $24.45 | +71.78% | 4 | Sep 11, 2024 | |
| TSBX Turnstone Biologics | Maintains: Buy | $12 → $10 | $0.50 | +1,889.65% | 2 | Aug 19, 2024 | |
| LLY Eli Lilly | Maintains: Buy | $1,000 → $1,125 | $903.25 | +24.55% | 8 | Aug 9, 2024 | |
| AMGN Amgen | Maintains: Neutral | $325 → $330 | $314.90 | +4.80% | 9 | Aug 7, 2024 | |
| MRK Merck & Co. | Maintains: Buy | $150 → $145 | $106.38 | +36.30% | 6 | Jul 31, 2024 | |
| LYEL Lyell Immunopharma | Maintains: Buy | $9 → $6 | $1.15 | +421.74% | 2 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $45 | $45.40 | -0.88% | 2 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $80 | $51.43 | +55.55% | 1 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $180 → $170 | $165.86 | +2.50% | 3 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $710 → $720 | $941.39 | -23.52% | 17 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $38 | $27.36 | +38.89% | 2 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $260 | $182.98 | +42.09% | 11 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $0.58 | +1,108.15% | 4 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $48 | $51.75 | -7.25% | 2 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $45 → $30 | $48.76 | -38.47% | 3 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $68 → $60 | $53.06 | +13.08% | 8 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 | $16.03 | -50.09% | 2 | Dec 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $13.31 | +35.24% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $23 → $14 | $7.52 | +86.17% | 2 | Sep 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $88 → $95 | $87.23 | +8.91% | 5 | Sep 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $10 → $8 | $2.70 | +196.30% | 4 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $17 | $2.52 | +574.60% | 1 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $14 | $2.69 | +420.45% | 3 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $45 | $28.86 | +55.93% | 6 | Apr 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $4.96 | +908.06% | 1 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $24 | $5.70 | +321.05% | 4 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $4 | $4.13 | -3.15% | 2 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $37 → $34 | $26.84 | +26.68% | 2 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $2.58 | +985.27% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $1.53 | +2,122.22% | 1 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $56 | $14.87 | +276.60% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $35 | $2.05 | +1,607.32% | 4 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $525 | $6.86 | +7,558.64% | 1 | Nov 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $1.60 | +2,525.00% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $46.00 | +139.13% | 1 | Oct 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $5.85 | +241.88% | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $1.54 | +1,198.70% | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.50 | +700.00% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underperform | $9 | $2.81 | +220.28% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $9.74 | +516.02% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $7 | $5.70 | +22.81% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $23 | $13.11 | +75.44% | 3 | Aug 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $90 → $82 | $65.17 | +25.82% | 9 | May 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $100 → $95 | $352.58 | -73.06% | 6 | Mar 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $60 → $16 | $0.68 | +2,252.60% | 3 | Dec 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $43 → $40 | $42.48 | -5.84% | 7 | Nov 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $135 | $115.08 | +17.31% | 2 | Aug 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $16.59 | - | 4 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $20 | $3.98 | +402.51% | 4 | May 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | n/a | $52.75 | - | 2 | Apr 5, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $180 → $200 | $470.05 | -57.45% | 3 | Feb 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $158 | $294.87 | -46.42% | 5 | Nov 8, 2017 |
AbbVie
Oct 18, 2024
Maintains: Neutral
Price Target: $185 → $195
Current: $187.88
Upside: +3.79%
Tyra Biosciences
Oct 18, 2024
Upgrades: Buy
Price Target: $22 → $31
Current: $28.24
Upside: +9.77%
BioMarin Pharmaceutical
Sep 17, 2024
Maintains: Buy
Price Target: $130 → $115
Current: $69.98
Upside: +64.33%
Moderna
Sep 13, 2024
Maintains: Neutral
Price Target: $130 → $110
Current: $53.39
Upside: +106.03%
BridgeBio Pharma
Sep 11, 2024
Maintains: Buy
Price Target: $42
Current: $24.45
Upside: +71.78%
Turnstone Biologics
Aug 19, 2024
Maintains: Buy
Price Target: $12 → $10
Current: $0.50
Upside: +1,889.65%
Eli Lilly
Aug 9, 2024
Maintains: Buy
Price Target: $1,000 → $1,125
Current: $903.25
Upside: +24.55%
Amgen
Aug 7, 2024
Maintains: Neutral
Price Target: $325 → $330
Current: $314.90
Upside: +4.80%
Merck & Co.
Jul 31, 2024
Maintains: Buy
Price Target: $150 → $145
Current: $106.38
Upside: +36.30%
Lyell Immunopharma
Jun 27, 2024
Maintains: Buy
Price Target: $9 → $6
Current: $1.15
Upside: +421.74%
Jun 13, 2024
Maintains: Buy
Price Target: $40 → $45
Current: $45.40
Upside: -0.88%
May 10, 2024
Initiates: Buy
Price Target: $80
Current: $51.43
Upside: +55.55%
Apr 17, 2024
Maintains: Neutral
Price Target: $180 → $170
Current: $165.86
Upside: +2.50%
Apr 12, 2024
Maintains: Underperform
Price Target: $710 → $720
Current: $941.39
Upside: -23.52%
Apr 12, 2024
Maintains: Buy
Price Target: $40 → $38
Current: $27.36
Upside: +38.89%
Apr 12, 2024
Maintains: Neutral
Price Target: $280 → $260
Current: $182.98
Upside: +42.09%
Mar 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $0.58
Upside: +1,108.15%
Mar 13, 2024
Maintains: Buy
Price Target: $24 → $48
Current: $51.75
Upside: -7.25%
Jan 3, 2024
Downgrades: Neutral
Price Target: $45 → $30
Current: $48.76
Upside: -38.47%
Jan 3, 2024
Downgrades: Neutral
Price Target: $68 → $60
Current: $53.06
Upside: +13.08%
Dec 15, 2023
Downgrades: Neutral
Price Target: $8
Current: $16.03
Upside: -50.09%
Oct 10, 2023
Initiates: Buy
Price Target: $18
Current: $13.31
Upside: +35.24%
Sep 8, 2023
Downgrades: Neutral
Price Target: $23 → $14
Current: $7.52
Upside: +86.17%
Sep 8, 2023
Upgrades: Buy
Price Target: $88 → $95
Current: $87.23
Upside: +8.91%
Aug 21, 2023
Maintains: Underperform
Price Target: $10 → $8
Current: $2.70
Upside: +196.30%
Aug 21, 2023
Maintains: Buy
Price Target: $19 → $17
Current: $2.52
Upside: +574.60%
Jul 20, 2023
Reinstates: Buy
Price Target: $14
Current: $2.69
Upside: +420.45%
Apr 21, 2023
Maintains: Neutral
Price Target: $50 → $45
Current: $28.86
Upside: +55.93%
Jan 5, 2023
Initiates: Buy
Price Target: $50
Current: $4.96
Upside: +908.06%
Nov 1, 2022
Downgrades: Underperform
Price Target: $24
Current: $5.70
Upside: +321.05%
Jun 8, 2022
Downgrades: Neutral
Price Target: $12 → $4
Current: $4.13
Upside: -3.15%
Dec 29, 2021
Maintains: Buy
Price Target: $37 → $34
Current: $26.84
Upside: +26.68%
Aug 10, 2021
Initiates: Buy
Price Target: $28
Current: $2.58
Upside: +985.27%
Jul 13, 2021
Initiates: Buy
Price Target: $34
Current: $1.53
Upside: +2,122.22%
May 7, 2021
Upgrades: Buy
Price Target: $56
Current: $14.87
Upside: +276.60%
Jan 15, 2021
Downgrades: Neutral
Price Target: $35
Current: $2.05
Upside: +1,607.32%
Nov 23, 2020
Initiates: Buy
Price Target: $525
Current: $6.86
Upside: +7,558.64%
Oct 20, 2020
Initiates: Buy
Price Target: $42
Current: $1.60
Upside: +2,525.00%
Oct 5, 2020
Initiates: Buy
Price Target: $110
Current: $46.00
Upside: +139.13%
Sep 15, 2020
Reinstates: Buy
Price Target: $20
Current: $5.85
Upside: +241.88%
Sep 8, 2020
Reinstates: Buy
Price Target: $20
Current: $1.54
Upside: +1,198.70%
Aug 4, 2020
Initiates: Buy
Price Target: $20
Current: $2.50
Upside: +700.00%
Jun 25, 2020
Reinstates: Underperform
Price Target: $9
Current: $2.81
Upside: +220.28%
Jun 25, 2020
Reinstates: Buy
Price Target: $60
Current: $9.74
Upside: +516.02%
Jun 25, 2020
Initiates: Underperform
Price Target: $7
Current: $5.70
Upside: +22.81%
Aug 5, 2019
Maintains: Equal-Weight
Price Target: $15 → $23
Current: $13.11
Upside: +75.44%
May 3, 2019
Downgrades: Equal-Weight
Price Target: $90 → $82
Current: $65.17
Upside: +25.82%
Mar 1, 2019
Maintains: Underweight
Price Target: $100 → $95
Current: $352.58
Upside: -73.06%
Dec 20, 2018
Downgrades: Equal-Weight
Price Target: $60 → $16
Current: $0.68
Upside: +2,252.60%
Nov 6, 2018
Maintains: Equal-Weight
Price Target: $43 → $40
Current: $42.48
Upside: -5.84%
Aug 1, 2018
Maintains: Overweight
Price Target: $100 → $135
Current: $115.08
Upside: +17.31%
May 21, 2018
Downgrades: Underweight
Price Target: n/a
Current: $16.59
Upside: -
May 3, 2018
Maintains: Equal-Weight
Price Target: $16 → $20
Current: $3.98
Upside: +402.51%
Apr 5, 2018
Downgrades: Equal-Weight
Price Target: n/a
Current: $52.75
Upside: -
Feb 1, 2018
Maintains: Overweight
Price Target: $180 → $200
Current: $470.05
Upside: -57.45%
Nov 8, 2017
Maintains: Overweight
Price Target: $127 → $158
Current: $294.87
Upside: -46.42%